Growth hormone therapy in short children born small for gestational age: effects on abdominal fat partitioning and circulating follistatin and high-molecular-weight adiponectin.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Follistatin-344.

A high sensitivity to insulin and a low amount of sc fat are among the hallmarks of short children born small for gestational age (SGA).

Who Took Part

According to the abstract, 35 children were involved.

The age groups tagged for this paper are infants and children, both men and women.

Patients included 35 short SGA children (mean age 7 yr, height -3.1 sd).

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

The study was conducted at a university hospital.

What Was Measured

Topics PubMed links to this paper include Abdominal Fat, Adiponectin, Adipose Tissue, Birth Weight, Blood Glucose, Body Height and Body Mass Index.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Follistatin-344 in 35 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2010 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the Follistatin-344 compound page, all human trials.